Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.41 |
| ▸ | GYS1 | P13807 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.38 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22753452 | 0.95 | MEN1 (0.46) | KMT2AMEN1PARP1HSD17B1HSD17B2 | |
| SCHEMBL22434466 | 0.92 | KMT2A (0.44) | KMT2AMEN1PARP1HSD17B1HSD17B2 | |
| SCHEMBL22404402 | 0.92 | MEN1 (0.44) | KMT2AMEN1PARP1HSD17B1HSD17B2 | |
| SCHEMBL20614484 | 0.87 | MEN1 (0.40) | KMT2AMEN1PARP1HSD17B1HSD17B2 | |
| SCHEMBL8171448 | 0.85 | KMT2A (0.53) | KMT2AMEN1HSD17B1HSD17B2SLC7A5 | |
| SCHEMBL10160068 | 0.83 | KMT2A (0.49) | KMT2AMEN1HSD17B1HSD17B2SLC7A5 | |
| SCHEMBL15592780 | 0.83 | KMT2A (0.54) | KMT2AMEN1HSD17B1HSD17B2SLC7A5 | |
| SCHEMBL22352080 | 0.80 | ACACB (0.40) | KMT2AMEN1PARP1HSD17B1HSD17B2 | |
| SCHEMBL18970421 | 0.80 | KMT2A (0.61) | KMT2AMEN1HSD17B1HSD17B2ACACB | |
| SCHEMBL18717377 | 0.79 | PARP1 (0.57) | KMT2AMEN1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20210046145-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10857196-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200283482-A1 | BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2020-09-10 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| WO-2019034868-A1 | BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034866-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857196-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | KMT2A 4757/4885MEN1 938/4885PARP1 3069/4885 |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | KMT2A 4757/4885MEN1 938/4885PARP1 3069/4885 |
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | STING1, BID, VIP | KMT2A 3919/4885MEN1 1257/4885PARP1 417/4885 |
| US-20210046145-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | KMT2A 4757/4885MEN1 938/4885PARP1 3069/4885 |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | VIP, NGLY1, GRPR | KMT2A 4824/4885MEN1 867/4885PARP1 3162/4885 |
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | KMT2A 4757/4885MEN1 938/4885PARP1 3069/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | KMT2A 4757/4885MEN1 938/4885PARP1 3069/4885 |
| US-20200283482-A1 | BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF | PRRC2A, GRPR, QRFPR | KMT2A 2394/4885MEN1 599/4885PARP1 1174/4885 |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | KMT2A 4757/4885MEN1 938/4885PARP1 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.